Dermatofibrosarcoma Protuberans: Our Experience of 59 Cases

Overview

Journal Oncol Lett

Specialty Oncology

Date 2012 Nov 20

PMID 23162649

Citations 20

Authors

Alessio Stivala

Giuseppe A G Lombardo

Gianluca Pompili

Maria Stella Tarico

Filippo Fraggetta

Rosario Emanuele Perrotta

Affiliations

Soon will be listed here.

Abstract

Dermatofibrosarcoma protuberans (DFSP) is a rare soft tissue tumor with intermediate malignancy. It is initially located on the skin from where it is able to infiltrate the deep structures and has a tendency to recur locally following inadequate excision. A t(17;22)(q22;q13) chromosome trans-location is the main cytogenetic alteration responsible for the onset of DFSP. Treatment options include complete surgical excision by performing conventional surgery with wide margins (>3 cm) or Mohs micrographic surgery. A retrospective study was conducted in our Department of Plastic and Reconstructive Surgery and all data were collected from medical records of 59 DFSP patients within this department from 1999 to 2011. A total of 13 of 59 (22%) cases were treated with conventional excision; 3 (5%) cases resulted in tumor-free margins, 8 (14%) cases required surgical revision and 2 (3%) cases lead to recurrence. A total of 46 of 59 (78%) cases were treated with wide excision; 43 (73%) cases resulted in tumor-free margins, 3 (5%) cases required surgical revision and 0 (0%) cases lead to recurrence. In conclusion, the data collected reveal the controversy surrounding the adoption of general guidelines regarding safe margins. Further studies are required to investigate the possibility of obtaining genotypically altered margins from margins that may appear phenotypically healthy.

Citing Articles

Dermatofibrosarcoma protuberans in a pre-adolescent child.

Wickramasinghe V, Saranga K, Piyarathne S, Prashantha A, Liyanage A Int J Surg Case Rep. 2023; 110:108761.

PMID: 37666158 PMC: 10509873. DOI: 10.1016/j.ijscr.2023.108761.

Clinical, dermoscopic, radiological and histopathological features of dermatofibrosarcoma protuberans.

Adya K, Panchagavi A, Thrupthi A, Inamadar A BMJ Case Rep. 2023; 16(2).

PMID: 36750297 PMC: 9906293. DOI: 10.1136/bcr-2022-254255.

Dermatofibrosarcoma Protuberans Over Right Lumbar Region: A Case Report.

Pathak B, Maimoon S Cureus. 2023; 15(1):e33208.

PMID: 36733580 PMC: 9887664. DOI: 10.7759/cureus.33208.

Reconstruction options in recurrent dermatofibrosarcoma protuberans:A scoping review.

Mago V, Pasricha A Rare Tumors. 2022; 14:20363613221123951.

PMID: 36341143 PMC: 9630893. DOI: 10.1177/20363613221123951.

Recurrent Dermatofibrosarcoma Protuberance: A Case Report.

Shah S, Regmee S, Maharjan D, Thapa P JNMA J Nepal Med Assoc. 2022; 59(243):1192-1195.

PMID: 35199742 PMC: 9124319. DOI: 10.31729/jnma.7187.

References

Bukhari I, Al Akloby O, Bedaiwi Y . Dermatofibrosarcoma protuberans at the site of a central venous line. Case report. Am J Clin Dermatol. 2005; 6(1):61-4. DOI: 10.2165/00128071-200506010-00007. View

Fletcher C . Giant cell fibroblastoma of soft tissue: a clinicopathological and immunohistochemical study. Histopathology. 1988; 13(5):499-508. DOI: 10.1111/j.1365-2559.1988.tb02074.x. View

Diwan A, Horenstein M . Dermatofibrosarcoma protuberans association with nuchal-type fibroma. J Cutan Pathol. 2003; 31(1):62-6. DOI: 10.1046/j.0303-6987.2004.0129.x. View

Chuang T, Su W, Muller S . Incidence of cutaneous T cell lymphoma and other rare skin cancers in a defined population. J Am Acad Dermatol. 1990; 23(2 Pt 1):254-6. DOI: 10.1016/0190-9622(90)70208-y. View

Dim-Jamora K, Perone J . Management of cutaneous tumors with mohs micrographic surgery. Semin Plast Surg. 2010; 22(4):247-56. PMC: 2884874. DOI: 10.1055/s-0028-1095884. View

Kim G . Status report on the management of dermatofibrosarcoma protuberans: is there a viable role for the use of imatinib mesylate? In which cases may it be therapeutically helpful and in which cases not?. J Clin Aesthet Dermatol. 2011; 4(3):17-26. PMC: 3070469. View

Chang C, Jacobs I, Salti G . Outcomes of surgery for dermatofibrosarcoma protuberans. Eur J Surg Oncol. 2004; 30(3):341-5. DOI: 10.1016/j.ejso.2003.12.005. View

Kamino H, Jacobson M . Dermatofibroma extending into the subcutaneous tissue. Differential diagnosis from dermatofibrosarcoma protuberans. Am J Surg Pathol. 1990; 14(12):1156-64. DOI: 10.1097/00000478-199012000-00008. View

Abenoza P, Lillemoe T . CD34 and factor XIIIa in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans. Am J Dermatopathol. 1993; 15(5):429-34. DOI: 10.1097/00000372-199310000-00003. View

10.

Bandarchi B, Ma L, Marginean C, Hafezi S, Zubovits J, Rasty G . D2-40, a novel immunohistochemical marker in differentiating dermatofibroma from dermatofibrosarcoma protuberans. Mod Pathol. 2010; 23(3):434-8. DOI: 10.1038/modpathol.2009.176. View

11.

Terrier-Lacombe M, Guillou L, Maire G, Terrier P, Ranchere Vince D, de Saint Aubain Somerhausen N . Dermatofibrosarcoma protuberans, giant cell fibroblastoma, and hybrid lesions in children: clinicopathologic comparative analysis of 28 cases with molecular data--a study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol. 2002; 27(1):27-39. DOI: 10.1097/00000478-200301000-00004. View

12.

Bashara M, Jules K, Potter G . Dermatofibrosarcoma protuberans: 4 years after local trauma. J Foot Surg. 1992; 31(2):160-5. View

13.

Mbonde M, Amir H, Kitinya J . Dermatofibrosarcoma protuberans: a clinicopathological study in an African population. East Afr Med J. 1996; 73(6):410-3. View

14.

Love W, Keiler S, Tamburro J, Honda K, Gosain A, Bordeaux J . Surgical management of congenital dermatofibrosarcoma protuberans. J Am Acad Dermatol. 2009; 61(6):1014-23. DOI: 10.1016/j.jaad.2009.05.028. View

15.

Gooskens S, Oranje A, Van Adrichem L, de Waard-van der Spek F, den Hollander J, van de Ven C . Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP). Pediatr Blood Cancer. 2010; 55(2):369-73. DOI: 10.1002/pbc.22494. View

16.

Rutgers E, Kroon B, Gortzak E . Dermatofibrosarcoma protuberans: treatment and prognosis. Eur J Surg Oncol. 1992; 18(3):241-8. View

17.

SIMON M, Pedeutour F, Sirvent N, Grosgeorge J, Minoletti F, Coindre J . Deregulation of the platelet-derived growth factor B-chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant-cell fibroblastoma. Nat Genet. 1997; 15(1):95-8. DOI: 10.1038/ng0197-95. View

18.

Pedeutour F, SIMON M, Minoletti F, Sozzi G, Pierotti M, Hecht F . Ring 22 chromosomes in dermatofibrosarcoma protuberans are low-level amplifiers of chromosome 17 and 22 sequences. Cancer Res. 1995; 55(11):2400-3. View

19.

Martin L, Piette F, Blanc P, Mortier L, Avril M, Delaunay M . Clinical variants of the preprotuberant stage of dermatofibrosarcoma protuberans. Br J Dermatol. 2005; 153(5):932-6. DOI: 10.1111/j.1365-2133.2005.06823.x. View

20.

Kutzner H . Expression of the human progenitor cell antigen CD34 (HPCA-1) distinguishes dermatofibrosarcoma protuberans from fibrous histiocytoma in formalin-fixed, paraffin-embedded tissue. J Am Acad Dermatol. 1993; 28(4):613-7. DOI: 10.1016/0190-9622(93)70083-6. View